Angiotensin receptor blocker use and gastro‐oesophageal cancer survival: a population‐based cohort study. Issue 2 (3rd November 2017)

• Record Type: Journal Article
• Authors: Busby, J.; McMenamin, Ú.; Spence, A.; Johnston, B. T.; Hughes, C.; Cardwell, C. R.
• Is Part Of: Alimentary pharmacology & therapeutics. Volume 47:Issue 2(2018)
• Page Start: 279
• Page End: 288
• Publication Date: 2017-11-03
• Subjects: Digestive organs -- Diseases -- Treatment -- Periodicals; Digestive organs -- Effect of drugs on -- Periodicals; Gastrointestinal system -- Diseases -- Treatment -- Periodicals; Gastrointestinal system -- Effect of drugs on -- Periodicals; 615.73
• DOI: 10.1111/apt.14388
• Languages: English
• ISSNs: 0269-2813

Abstract

Summary: Background: Angiotensin receptor blockers (ARBs; including candesartan, losartan, olmesartan and valsartan) are widely used to treat hypertension, heart failure and diabetic neuropathy. There is considerable pre‐clinical evidence that ARBs can reduce cancer progression, particularly for gastric cancer. Despite this, epidemiological studies have yet to assess the impact of ARB use on gastro‐oesophageal cancer survival. Aim: To investigate the association between post‐diagnosis ARB use and gastro‐oesophageal cancer survival. Methods: We selected a cohort of patients with newly‐diagnosed gastro‐oesophageal cancer between 1998 and 2012 from English cancer registries. We linked to prescription and clinical records from the Clinical Practice Research Datalink, and to death records from the Office for National Statistics. We used time‐dependant Cox‐regression models to calculate hazard ratios (HRs) comparing gastro‐oesophageal cancer‐specific mortality between post‐diagnosis ARB users and non‐users, after adjusting for demographics, comorbidities and post‐diagnosis aspirin or statin use. Results: Our cohort included 5124 gastro‐oesophageal cancer patients, of which 360 used ARBs, and 3345 died due to their gastro‐oesophageal cancer during follow‐up. After adjustment, ARB users had moderately lower risk of gastro‐oesophageal cancer mortality than the non‐users (HR = 0.83, 95% CI 0.71‐0.98). There was evidence of a dose–response relationship with the lowest HRs observed among patients receiving at least 2 years of prescriptions (HR = 0.42, 95% CI 0.25‐0.72). Conclusions: In this large population‐based gastro‐oesophageal cancer cohort, we found moderately reduced cancer‐specific mortality among ARB users. However, confirmation in further independent epidemiological studies with sufficient staging information is required.